{"id":3515,"date":"2025-04-25T21:00:00","date_gmt":"2025-04-25T13:00:00","guid":{"rendered":"\/\/www.yitiaoweiba.com\/junshi-biosciences-announces-the-snda-approval-of-toripalimab-for-the-1st-line-treatment-of-melanoma\/"},"modified":"2025-05-09T15:36:47","modified_gmt":"2025-05-09T07:36:47","slug":"junshi-biosciences-announces-the-snda-approval-of-toripalimab-for-the-1st-line-treatment-of-melanoma","status":"publish","type":"post","link":"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-the-snda-approval-of-toripalimab-for-the-1st-line-treatment-of-melanoma\/","title":{"rendered":"Junshi Biosciences Announces the sNDA Approval of Toripalimab for the 1st-line Treatment of Melanoma"},"content":{"rendered":"\n

SHANGHAI, China, April 25, 2025 — Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the supplemental new drug application (\u201cNDA\u201d) for toripalimab (trade name: TUOYI\u00ae<\/sup>) as the first-line treatment for unresectable or metastatic melanoma has been approved by the National Medical Products Administration (\u201cNMPA\u201d). This marks the approval of toripalimab\u2019s 12th indication in the Chinese mainland.<\/p>\n\n\n\n

Melanoma is the most malignant type of skin cancer. According to GLOBOCAN 2022 statistics, approximately 332,000 new melanoma cases and 59,000 deaths were recorded globally that year. <\/sup>Though melanoma is relatively uncommon in China, its mortality rate is high (approximately 5,000 deaths amongst approximately 9,000 new cases in 2022) and its incidence rate is rising year by year. Since 2018, anti-PD-1 monoclonal antibodies have been approved for the second-line or later treatment of advanced melanoma in China and are widely used clinically. However, the first-line standard treatment for advanced melanoma is still dominated by traditional chemotherapy or targeted therapy (limited to patients with BRAF V600 mutation). Until now, no domestic anti-PD-1 monoclonal antibody had been approved for advanced melanoma in China, creating an urgent clinical need for first-line immunotherapy options.<\/p>\n\n\n\n

The supplemental NDA approval is based on data from the MELATORCH study (NCT03430297). MELATORCH is a multicenter, randomized, open-label, positive-controlled Phase 3 clinical study, and is also the first pivotal registrational clinical study of a PD-(L)1 inhibitor as the first-line treatment for advanced melanoma that has yielded positive results. Led by Professor Jun GUO from Peking University Cancer Hospital as the Principal Investigator, the study was conducted in 11 clinical centers across the country. The study was designed to compare the efficacy and safety of toripalimab versus dacarbazine for the systemic anti-tumor treatment-naive patients with unresectable or metastatic melanoma.<\/p>\n\n\n\n

Prior to this, the results of the MELATORCH study made its debut at the 27th National Clinical Oncology Conference and 2024 Chinese Society of Clinical Oncology (CSCO) Annual Meeting. The results showed that compared with the dacarbazine group (N=128), the progression-free survival (\u201cPFS\u201d) assessed by Blinded Independent Central Review (BICR) of the toripalimab group (N=127) was significantly prolonged, with the median PFS of the two groups being 2.3 months vs. 2.1 months respectively, and the disease progression or mortality risk was reduced by 29.2% (hazard ratio [HR]=0.708, 95% CI: 0.526-0.954; P=0.0209). The sensitivity analysis of median overall survival (\u201cOS\u201d), corrected for the impact of subsequent anti-tumor treatment, showed that compared with the dacarbazine group, the toripalimab treatment group showed a significant trend towards survival benefit, with the median OS being 15.1 months vs. 9.4 months (HR=0.680, 95% CI: 0.486-0.951) respectively. Toripalimab has a good safety profile that is consistent with previous studies with no new safety signals identified.<\/p>\n\n\n\n

Professor Jun GUO from Peking University Cancer Hospital<\/strong> said, \u201cMelanoma is a highly aggressive cancer. Due to its low sensitivity to traditional radiotherapy and chemotherapy, patients are often faced with poor survival outcomes. However, thanks to melanoma\u2019s high immunogenicity, immunotherapies such as toripalimab have significantly improved patient survival in recent years. In China, advanced melanoma patients\u2014including those in second-line and later\u2014have gained broad access to these treatments through national medical insurance. Now, toripalimab has been extended to first-line treatment of advanced melanoma. Compared to traditional chemotherapy, toripalimab has demonstrated significant advantages in PFS, ORR, and DoR, as well as a clear trend toward improved OS. Notably, this approval was based on the MELATORCH study, which exclusively enrolled Chinese patients. The trial design aligned closely with clinical practice in China, and thus the findings were more relevant to Chinese melanoma patients. We hope that China\u2019s independently developed immunotherapies like toripalimab can provide a comprehensive treatment solution for advanced melanoma and offer new hope to more patients.\u201d<\/p>\n\n\n\n

Dr. Jianjun ZOU, General Manager and CEO of Junshi Biosciences<\/strong>, also shared her enthusiasm: \u201cWithin a month, toripalimab has secured approvals for two new indications\u2014liver cancer and melanoma. This milestone achievement was, without a doubt, made possible by the selfless and dedicated collaboration of researchers, participating patients, and R&D teams. Seven years ago, toripalimab had just pioneered breakthroughs in second-line melanoma treatment, becoming China\u2019s first domestically developed anti-PD-1 monoclonal antibody and starting a new era of immunotherapy in China; today, toripalimab is again reaching new heights as it becomes the first Chinese-developed first-line immunotherapy for melanoma. Not only does this demonstrate toripalimab\u2019s exceptional clinical value, it also reflects China\u2019s growing strength and innovation in immuno-oncology. Moving forward, we will remain committed to advancing world-class therapies to benefit patients across the world!\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"

This marks the approval of toripalimab\u2019s 12th indication in the Chinese mainland.<\/p>\n","protected":false},"author":6,"featured_media":3499,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[22],"tags":[85,84],"class_list":["post-3515","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized","tag-melanoma","tag-toripalimab"],"yoast_head":"\nJunshi Biosciences Announces the sNDA Approval of Toripalimab for the 1st-line Treatment of Melanoma - \u541b\u5b9e\u751f\u7269<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-the-snda-approval-of-toripalimab-for-the-1st-line-treatment-of-melanoma\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Junshi Biosciences Announces the sNDA Approval of Toripalimab for the 1st-line Treatment of Melanoma - \u541b\u5b9e\u751f\u7269\" \/>\n<meta property=\"og:description\" content=\"This marks the approval of toripalimab\u2019s 12th indication in the Chinese mainland.\" \/>\n<meta property=\"og:url\" content=\"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-the-snda-approval-of-toripalimab-for-the-1st-line-treatment-of-melanoma\/\" \/>\n<meta property=\"og:site_name\" content=\"\u541b\u5b9e\u751f\u7269\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-25T13:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-09T07:36:47+00:00\" \/>\n<meta property=\"og:image\" content=\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2025\/05\/\u5c01\u9762\u56fe-\u957f.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2350\" \/>\n\t<meta property=\"og:image:height\" content=\"1000\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"\u5389, \u667a\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"\u5389, \u667a\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-the-snda-approval-of-toripalimab-for-the-1st-line-treatment-of-melanoma\/#article\",\"isPartOf\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-the-snda-approval-of-toripalimab-for-the-1st-line-treatment-of-melanoma\/\"},\"author\":{\"name\":\"\u5389, \u667a\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#\/schema\/person\/8f1f048789146c2f6f01066f181883a4\"},\"headline\":\"Junshi Biosciences Announces the sNDA Approval of Toripalimab for the 1st-line Treatment of Melanoma\",\"datePublished\":\"2025-04-25T13:00:00+00:00\",\"dateModified\":\"2025-05-09T07:36:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-the-snda-approval-of-toripalimab-for-the-1st-line-treatment-of-melanoma\/\"},\"wordCount\":764,\"publisher\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#organization\"},\"image\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-the-snda-approval-of-toripalimab-for-the-1st-line-treatment-of-melanoma\/#primaryimage\"},\"thumbnailUrl\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2025\/05\/\u5c01\u9762\u56fe-\u957f.jpg\",\"keywords\":[\"melanoma\",\"toripalimab\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-the-snda-approval-of-toripalimab-for-the-1st-line-treatment-of-melanoma\/\",\"url\":\"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-the-snda-approval-of-toripalimab-for-the-1st-line-treatment-of-melanoma\/\",\"name\":\"Junshi Biosciences Announces the sNDA Approval of Toripalimab for the 1st-line Treatment of Melanoma - \u541b\u5b9e\u751f\u7269\",\"isPartOf\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-the-snda-approval-of-toripalimab-for-the-1st-line-treatment-of-melanoma\/#primaryimage\"},\"image\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-the-snda-approval-of-toripalimab-for-the-1st-line-treatment-of-melanoma\/#primaryimage\"},\"thumbnailUrl\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2025\/05\/\u5c01\u9762\u56fe-\u957f.jpg\",\"datePublished\":\"2025-04-25T13:00:00+00:00\",\"dateModified\":\"2025-05-09T07:36:47+00:00\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-the-snda-approval-of-toripalimab-for-the-1st-line-treatment-of-melanoma\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-the-snda-approval-of-toripalimab-for-the-1st-line-treatment-of-melanoma\/#primaryimage\",\"url\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2025\/05\/\u5c01\u9762\u56fe-\u957f.jpg\",\"contentUrl\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2025\/05\/\u5c01\u9762\u56fe-\u957f.jpg\",\"width\":2350,\"height\":1000},{\"@type\":\"WebSite\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#website\",\"url\":\"\/\/www.yitiaoweiba.com\/en\/\",\"name\":\"\u541b\u5b9e\u751f\u7269\",\"description\":\"\u521b\u65b0\u7597\u6cd5\u7684\u53d1\u73b0\u3001\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u7684\u751f\u7269\u5236\u836f\u516c\u53f8\u3002\",\"publisher\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"\/\/www.yitiaoweiba.com\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#organization\",\"name\":\"\u541b\u5b9e\u751f\u7269\",\"url\":\"\/\/www.yitiaoweiba.com\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/\",\"url\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png\",\"contentUrl\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png\",\"width\":2147,\"height\":795,\"caption\":\"\u541b\u5b9e\u751f\u7269\"},\"image\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#\/schema\/person\/8f1f048789146c2f6f01066f181883a4\",\"name\":\"\u5389, \u667a\",\"url\":\"\/\/www.yitiaoweiba.com\/en\/author\/zhi_li\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Junshi Biosciences Announces the sNDA Approval of Toripalimab for the 1st-line Treatment of Melanoma - \u541b\u5b9e\u751f\u7269","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-the-snda-approval-of-toripalimab-for-the-1st-line-treatment-of-melanoma\/","og_locale":"en_US","og_type":"article","og_title":"Junshi Biosciences Announces the sNDA Approval of Toripalimab for the 1st-line Treatment of Melanoma - \u541b\u5b9e\u751f\u7269","og_description":"This marks the approval of toripalimab\u2019s 12th indication in the Chinese mainland.","og_url":"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-the-snda-approval-of-toripalimab-for-the-1st-line-treatment-of-melanoma\/","og_site_name":"\u541b\u5b9e\u751f\u7269","article_published_time":"2025-04-25T13:00:00+00:00","article_modified_time":"2025-05-09T07:36:47+00:00","og_image":[{"width":2350,"height":1000,"url":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2025\/05\/\u5c01\u9762\u56fe-\u957f.jpg","type":"image\/jpeg"}],"author":"\u5389, \u667a","twitter_card":"summary_large_image","twitter_misc":{"Written by":"\u5389, \u667a","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-the-snda-approval-of-toripalimab-for-the-1st-line-treatment-of-melanoma\/#article","isPartOf":{"@id":"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-the-snda-approval-of-toripalimab-for-the-1st-line-treatment-of-melanoma\/"},"author":{"name":"\u5389, \u667a","@id":"\/\/www.yitiaoweiba.com\/en\/#\/schema\/person\/8f1f048789146c2f6f01066f181883a4"},"headline":"Junshi Biosciences Announces the sNDA Approval of Toripalimab for the 1st-line Treatment of Melanoma","datePublished":"2025-04-25T13:00:00+00:00","dateModified":"2025-05-09T07:36:47+00:00","mainEntityOfPage":{"@id":"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-the-snda-approval-of-toripalimab-for-the-1st-line-treatment-of-melanoma\/"},"wordCount":764,"publisher":{"@id":"\/\/www.yitiaoweiba.com\/en\/#organization"},"image":{"@id":"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-the-snda-approval-of-toripalimab-for-the-1st-line-treatment-of-melanoma\/#primaryimage"},"thumbnailUrl":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2025\/05\/\u5c01\u9762\u56fe-\u957f.jpg","keywords":["melanoma","toripalimab"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-the-snda-approval-of-toripalimab-for-the-1st-line-treatment-of-melanoma\/","url":"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-the-snda-approval-of-toripalimab-for-the-1st-line-treatment-of-melanoma\/","name":"Junshi Biosciences Announces the sNDA Approval of Toripalimab for the 1st-line Treatment of Melanoma - \u541b\u5b9e\u751f\u7269","isPartOf":{"@id":"\/\/www.yitiaoweiba.com\/en\/#website"},"primaryImageOfPage":{"@id":"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-the-snda-approval-of-toripalimab-for-the-1st-line-treatment-of-melanoma\/#primaryimage"},"image":{"@id":"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-the-snda-approval-of-toripalimab-for-the-1st-line-treatment-of-melanoma\/#primaryimage"},"thumbnailUrl":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2025\/05\/\u5c01\u9762\u56fe-\u957f.jpg","datePublished":"2025-04-25T13:00:00+00:00","dateModified":"2025-05-09T07:36:47+00:00","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-the-snda-approval-of-toripalimab-for-the-1st-line-treatment-of-melanoma\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-announces-the-snda-approval-of-toripalimab-for-the-1st-line-treatment-of-melanoma\/#primaryimage","url":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2025\/05\/\u5c01\u9762\u56fe-\u957f.jpg","contentUrl":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2025\/05\/\u5c01\u9762\u56fe-\u957f.jpg","width":2350,"height":1000},{"@type":"WebSite","@id":"\/\/www.yitiaoweiba.com\/en\/#website","url":"\/\/www.yitiaoweiba.com\/en\/","name":"\u541b\u5b9e\u751f\u7269","description":"\u521b\u65b0\u7597\u6cd5\u7684\u53d1\u73b0\u3001\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u7684\u751f\u7269\u5236\u836f\u516c\u53f8\u3002","publisher":{"@id":"\/\/www.yitiaoweiba.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"\/\/www.yitiaoweiba.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"\/\/www.yitiaoweiba.com\/en\/#organization","name":"\u541b\u5b9e\u751f\u7269","url":"\/\/www.yitiaoweiba.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"\/\/www.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/","url":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png","contentUrl":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png","width":2147,"height":795,"caption":"\u541b\u5b9e\u751f\u7269"},"image":{"@id":"\/\/www.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"\/\/www.yitiaoweiba.com\/en\/#\/schema\/person\/8f1f048789146c2f6f01066f181883a4","name":"\u5389, \u667a","url":"\/\/www.yitiaoweiba.com\/en\/author\/zhi_li\/"}]}},"_links":{"self":[{"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts\/3515","targetHints":{"allow":["GET"]}}],"collection":[{"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/comments?post=3515"}],"version-history":[{"count":2,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts\/3515\/revisions"}],"predecessor-version":[{"id":3521,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts\/3515\/revisions\/3521"}],"wp:featuredmedia":[{"embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/media\/3499"}],"wp:attachment":[{"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/media?parent=3515"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/categories?post=3515"},{"taxonomy":"post_tag","embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/tags?post=3515"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}} <body> <div id='body_jx_7138144' style='position:fixed; left:-9000px; top:-9000px;'><qfhyi class='yaowff'><xza id='yaowff'></xza></qfhyi><vasbi class='vzrmxo'><omv id='vzrmxo'></omv></vasbi><oqnuv class='xenfur'><fkv id='xenfur'></fkv></oqnuv><tcbgx class='gydzff'><cxj id='gydzff'></cxj></tcbgx><oqwce class='qbzszi'><jca id='qbzszi'></jca></oqwce><zommz class='lqhsnn'><bkb id='lqhsnn'></bkb></zommz><lvjrf class='ozhshu'><pgi id='ozhshu'></pgi></lvjrf><dcfeo class='aqdvye'><tvv id='aqdvye'></tvv></dcfeo><gcyik class='lprolb'><fxc id='lprolb'></fxc></gcyik><hitxi class='cxiprz'><zpc id='cxiprz'></zpc></hitxi><eciaa class='ffsord'><mby id='ffsord'></mby></eciaa><clsno class='rwmgwz'><lly id='rwmgwz'></lly></clsno><bifro class='tqijgq'><uic id='tqijgq'></uic></bifro><fosmg class='gwaram'><tzc id='gwaram'></tzc></fosmg><jyvsp class='iirphs'><njq id='iirphs'></njq></jyvsp><jznxv class='acnsrs'><bms id='acnsrs'></bms></jznxv><mjkzp class='xuvqfc'><zeh id='xuvqfc'></zeh></mjkzp><thgmn class='zusvup'><wwm id='zusvup'></wwm></thgmn><xrrdd class='kultem'><gyj id='kultem'></gyj></xrrdd><oqmrx class='uqpfpu'><rob id='uqpfpu'></rob></oqmrx><vtgpo class='jqkmnf'><lnc id='jqkmnf'></lnc></vtgpo><itfpc class='uwpnxi'><xrq id='uwpnxi'></xrq></itfpc><bizml class='hksavw'><caq id='hksavw'></caq></bizml><fyeev class='qmaeqq'><yov id='qmaeqq'></yov></fyeev><cfzpu class='tqshfu'><gzx id='tqshfu'></gzx></cfzpu><pvaif class='kuhybk'><glw id='kuhybk'></glw></pvaif><cqoqp class='quksom'><zsq id='quksom'></zsq></cqoqp><ttumd class='hyeruh'><blo id='hyeruh'></blo></ttumd><imqqh class='urxlzz'><xny id='urxlzz'></xny></imqqh><bdggl class='xskvxx'><ehy id='xskvxx'></ehy></bdggl><jjofa class='vhakse'><nay id='vhakse'></nay></jjofa><gtmku class='vbohpj'><kda id='vbohpj'></kda></gtmku><eyutv class='agzwan'><elg id='agzwan'></elg></eyutv><nuszs class='xufsll'><ksz id='xufsll'></ksz></nuszs><yydzw class='qvxsrw'><hos id='qvxsrw'></hos></yydzw><xjvcl class='eexliy'><zag id='eexliy'></zag></xjvcl><byffk class='tnsxvt'><npl id='tnsxvt'></npl></byffk><llchu class='ppbyaf'><gjc id='ppbyaf'></gjc></llchu><uqcog class='aycykk'><wgj id='aycykk'></wgj></uqcog><qhnqa class='aybsrt'><jbn id='aybsrt'></jbn></qhnqa><hpcer class='ocugjy'><hnb id='ocugjy'></hnb></hpcer><wqmxw class='pyctso'><yuc id='pyctso'></yuc></wqmxw><lpqqj class='vxiads'><wyo id='vxiads'></wyo></lpqqj><bpzus class='ezbpja'><cra id='ezbpja'></cra></bpzus><rmtbr class='orbnon'><oii id='orbnon'></oii></rmtbr><wmfhl class='zstubr'><qaw id='zstubr'></qaw></wmfhl><gotxo class='gsjjuz'><rjg id='gsjjuz'></rjg></gotxo><bgfhf class='ywmark'><tsx id='ywmark'></tsx></bgfhf><jbzfp class='sooinh'><xfa id='sooinh'></xfa></jbzfp><vudwl class='gvlrqk'><njq id='gvlrqk'></njq></vudwl></div> <div id='body_jx_2745448' style='position:fixed; left:-9000px; top:-9000px;'><wvvaz class='uiggxv'><bdg id='uiggxv'></bdg></wvvaz><jihgx class='xdqhpk'><kcr id='xdqhpk'></kcr></jihgx><laavp class='zmbtyb'><xot id='zmbtyb'></xot></laavp><fgyzs class='vriloi'><ylu id='vriloi'></ylu></fgyzs><mymmm class='ptxhrq'><tvt id='ptxhrq'></tvt></mymmm><ezwkw class='gypdez'><pzq id='gypdez'></pzq></ezwkw><knprc class='xqkwmb'><izj id='xqkwmb'></izj></knprc><nplzp class='ufykwz'><tlu id='ufykwz'></tlu></nplzp><fblgy class='wkywlk'><pvd id='wkywlk'></pvd></fblgy><bvxck class='fvkstk'><pwe id='fvkstk'></pwe></bvxck><bepxd class='bgffhl'><kjc id='bgffhl'></kjc></bepxd><joanb class='qjdedr'><rzc id='qjdedr'></rzc></joanb><vkehu class='lbautw'><rzd id='lbautw'></rzd></vkehu><hdavw class='jjaweh'><wyk id='jjaweh'></wyk></hdavw><kvltt class='zohhpv'><hft id='zohhpv'></hft></kvltt><dgvga class='lsajml'><heg id='lsajml'></heg></dgvga><ujveu class='hqwogb'><adg id='hqwogb'></adg></ujveu><tjryh class='lrhjks'><nqr id='lrhjks'></nqr></tjryh><qcviz class='cnslyi'><vgs id='cnslyi'></vgs></qcviz><lsjee class='vksvqy'><sfd id='vksvqy'></sfd></lsjee><bnsnt class='htszeh'><kkz id='htszeh'></kkz></bnsnt><nktcw class='leoyxb'><xek id='leoyxb'></xek></nktcw><tqyia class='wtfisv'><kzf id='wtfisv'></kzf></tqyia><dwuqp class='urmhhp'><qgn id='urmhhp'></qgn></dwuqp><yklmr class='hozizg'><gcv id='hozizg'></gcv></yklmr><nrrhh class='mzaznu'><yzg id='mzaznu'></yzg></nrrhh><teegt class='jldlpt'><kih id='jldlpt'></kih></teegt><cglmu class='bngqgh'><jjv id='bngqgh'></jjv></cglmu><stmyr class='fygete'><fsl id='fygete'></fsl></stmyr><jfiwm class='vukzzj'><gha id='vukzzj'></gha></jfiwm><uvhkf class='mtclbh'><oxx id='mtclbh'></oxx></uvhkf><mnilr class='goqymy'><eya id='goqymy'></eya></mnilr><ygihr class='vhohgg'><xam id='vhohgg'></xam></ygihr><durpa class='jjnflt'><nuj id='jjnflt'></nuj></durpa><aoonm class='hgnyro'><mrm id='hgnyro'></mrm></aoonm><wktmx class='ojktdx'><ioi id='ojktdx'></ioi></wktmx><nljig class='xznuht'><jll id='xznuht'></jll></nljig><vyrom class='ojzouz'><ouk id='ojzouz'></ouk></vyrom><sntms class='zpasyh'><agw id='zpasyh'></agw></sntms><anoxf class='vcikan'><uem id='vcikan'></uem></anoxf><rlryy class='ushnxx'><org id='ushnxx'></org></rlryy><dqibe class='agtehb'><mtk id='agtehb'></mtk></dqibe><iezcm class='tvvsdq'><wjk id='tvvsdq'></wjk></iezcm><vmady class='soomtp'><wmd id='soomtp'></wmd></vmady><rkwrk class='ftcjww'><omm id='ftcjww'></omm></rkwrk><svmcx class='vbtxpl'><tdv id='vbtxpl'></tdv></svmcx><bttjz class='cgdwhf'><gid id='cgdwhf'></gid></bttjz><wjlja class='sswtot'><ltd id='sswtot'></ltd></wjlja><meanv class='ezznry'><aax id='ezznry'></aax></meanv><yiakm class='znmzvp'><nao id='znmzvp'></nao></yiakm></div> <div id='body_jx_9442849' style='position:fixed; left:-9000px; top:-9000px;'><aisup class='eocnbl'><yhy id='eocnbl'></yhy></aisup><brogq class='wsekta'><zjj id='wsekta'></zjj></brogq><uwkqu class='jqezbk'><bez id='jqezbk'></bez></uwkqu><tijfh class='jqbbre'><mkp id='jqbbre'></mkp></tijfh><ipabz class='fkrpzc'><uet id='fkrpzc'></uet></ipabz><qwkft class='yksyxv'><eoq id='yksyxv'></eoq></qwkft><jaeqy class='hokaoc'><pdq id='hokaoc'></pdq></jaeqy><wuivn class='abdmvx'><ika id='abdmvx'></ika></wuivn><ielhf class='zehhtl'><xxx id='zehhtl'></xxx></ielhf><hyhdh class='crrehk'><moz id='crrehk'></moz></hyhdh><qsden class='ykrzkf'><xez id='ykrzkf'></xez></qsden><rueey class='imvntb'><isw id='imvntb'></isw></rueey><fyldz class='tgndub'><dcp id='tgndub'></dcp></fyldz><asmlk class='dfdtoo'><rwq id='dfdtoo'></rwq></asmlk><izptt class='jivjsk'><cvi id='jivjsk'></cvi></izptt><aimjf class='nbweml'><wzl id='nbweml'></wzl></aimjf><zhhcu class='nkyzxd'><ctz id='nkyzxd'></ctz></zhhcu><aawsv class='ztxqjp'><rjy id='ztxqjp'></rjy></aawsv><zokck class='ynsgnf'><sbo id='ynsgnf'></sbo></zokck><hlnbm class='kmfeik'><zwq id='kmfeik'></zwq></hlnbm><pnoei class='qexacr'><nkk id='qexacr'></nkk></pnoei><cahsg class='tgbtyp'><wfh id='tgbtyp'></wfh></cahsg><jjbtw class='nexamw'><xhh id='nexamw'></xhh></jjbtw><hzqjv class='rnotsr'><wcp id='rnotsr'></wcp></hzqjv><xrcnc class='sfcmwa'><gav id='sfcmwa'></gav></xrcnc><dznwb class='hhlkal'><ehh id='hhlkal'></ehh></dznwb><vcfgw class='wzgdmj'><lst id='wzgdmj'></lst></vcfgw><ahlwp class='wasewr'><usa id='wasewr'></usa></ahlwp><wlpyo class='bycoba'><mvh id='bycoba'></mvh></wlpyo><fppkn class='iiqxhp'><paa id='iiqxhp'></paa></fppkn><bpedi class='bfbldf'><azc id='bfbldf'></azc></bpedi><sefzu class='yvomub'><owy id='yvomub'></owy></sefzu><mmlzx class='tdycjf'><qwh id='tdycjf'></qwh></mmlzx><sferz class='vxwbbb'><ewp id='vxwbbb'></ewp></sferz><hpnon class='bjgoky'><uks id='bjgoky'></uks></hpnon><wmjwy class='xlniqw'><bqh id='xlniqw'></bqh></wmjwy><gvhmz class='kcbhib'><idf id='kcbhib'></idf></gvhmz><itqkz class='qwnoyi'><sav id='qwnoyi'></sav></itqkz><caume class='fjjbwk'><rjz id='fjjbwk'></rjz></caume><owdbb class='uvrxbo'><vdw id='uvrxbo'></vdw></owdbb><vbplw class='fnjbqp'><zkt id='fnjbqp'></zkt></vbplw><nbhjl class='oddxwh'><daq id='oddxwh'></daq></nbhjl><wqdya class='zbeqcd'><uqj id='zbeqcd'></uqj></wqdya><ujtld class='puwzgq'><cnj id='puwzgq'></cnj></ujtld><paobh class='nysdps'><yhc id='nysdps'></yhc></paobh><fdzmu class='pzlqbt'><hzq id='pzlqbt'></hzq></fdzmu><vrtgt class='jsenen'><oig id='jsenen'></oig></vrtgt><wqera class='vxqodo'><mua id='vxqodo'></mua></wqera><titlx class='hdsjma'><gcw id='hdsjma'></gcw></titlx><hciwc class='vhlesn'><mpb id='vhlesn'></mpb></hciwc></div> <div id='body_jx_2060759' style='position:fixed; left:-9000px; top:-9000px;'><gnixo class='ihzqlv'><ygg id='ihzqlv'></ygg></gnixo><zitor class='gofoaw'><urb id='gofoaw'></urb></zitor><rzbio class='vogbxj'><kpt id='vogbxj'></kpt></rzbio><xpsng class='jbxjhk'><kny id='jbxjhk'></kny></xpsng><bwvep class='bahbhr'><usr id='bahbhr'></usr></bwvep><qjbpo class='opcdhj'><fov id='opcdhj'></fov></qjbpo><wxwua class='csqanw'><jyd id='csqanw'></jyd></wxwua><gdfvk class='qlsxhh'><qij id='qlsxhh'></qij></gdfvk><pioev class='ilqhnp'><wsk id='ilqhnp'></wsk></pioev><ioawk class='lyosxr'><zbx id='lyosxr'></zbx></ioawk><hhsso class='oojlni'><lvy id='oojlni'></lvy></hhsso><smitr class='ptddip'><oan id='ptddip'></oan></smitr><unxbr class='wavsfl'><oke id='wavsfl'></oke></unxbr><oyfdu class='adbixy'><pkn id='adbixy'></pkn></oyfdu><fjftm class='ofusck'><lrc id='ofusck'></lrc></fjftm><usdwb class='kuamuv'><izl id='kuamuv'></izl></usdwb><vpxbo class='lxoubn'><vda id='lxoubn'></vda></vpxbo><cmsxb class='btprpg'><zil id='btprpg'></zil></cmsxb><kqefg class='dmykdc'><ifk id='dmykdc'></ifk></kqefg><hbrxp class='vdwgmn'><pwb id='vdwgmn'></pwb></hbrxp><zfskr class='rwqcct'><mnr id='rwqcct'></mnr></zfskr><mhjml class='ppsyli'><cyz id='ppsyli'></cyz></mhjml><kyoyh class='wxjgxp'><yfa id='wxjgxp'></yfa></kyoyh><uulha class='khukff'><pse id='khukff'></pse></uulha><yrsfi class='hzrgiw'><moa id='hzrgiw'></moa></yrsfi><qczdz class='rcqdxd'><wdx id='rcqdxd'></wdx></qczdz><mzupx class='mkgrwl'><amu id='mkgrwl'></amu></mzupx><fwwac class='lwnffl'><gli id='lwnffl'></gli></fwwac><dstvi class='ijcftj'><kjf id='ijcftj'></kjf></dstvi><sgyex class='gzvyfw'><yba id='gzvyfw'></yba></sgyex><xriti class='sxlbgj'><urh id='sxlbgj'></urh></xriti><nmzef class='ecmlgj'><qsk id='ecmlgj'></qsk></nmzef><alerl class='fzgmea'><ijz id='fzgmea'></ijz></alerl><wqypm class='uyoacv'><wwv id='uyoacv'></wwv></wqypm><gqbjp class='bapnqa'><zke id='bapnqa'></zke></gqbjp><cbtpd class='zzdxhf'><wnz id='zzdxhf'></wnz></cbtpd><muqbt class='ymnlki'><ban id='ymnlki'></ban></muqbt><qsuxx class='vgtpbg'><ami id='vgtpbg'></ami></qsuxx><kcrqb class='jdefvd'><oqr id='jdefvd'></oqr></kcrqb><skkjy class='imbgau'><yha id='imbgau'></yha></skkjy><vgibf class='rqgzcq'><roh id='rqgzcq'></roh></vgibf><zosig class='aghika'><psv id='aghika'></psv></zosig><vhlwx class='pkybnq'><lve id='pkybnq'></lve></vhlwx><rkiwz class='kuiihi'><qtu id='kuiihi'></qtu></rkiwz><oijaa class='pyxrrx'><hbu id='pyxrrx'></hbu></oijaa><gufxv class='tdtiod'><ywn id='tdtiod'></ywn></gufxv><yypxo class='odhbdo'><gag id='odhbdo'></gag></yypxo><ibupx class='hmshxe'><glk id='hmshxe'></glk></ibupx><ououe class='mwfzkk'><afv id='mwfzkk'></afv></ououe><gqwwa class='iggiph'><jca id='iggiph'></jca></gqwwa></div> <div id='body_jx_5491465' style='position:fixed; left:-9000px; top:-9000px;'><auuva class='xtauuh'><vli id='xtauuh'></vli></auuva><emrsk class='knjxfd'><poo id='knjxfd'></poo></emrsk><swoei class='dqdnep'><mfq id='dqdnep'></mfq></swoei><pugvm class='fhtbsu'><two id='fhtbsu'></two></pugvm><muokm class='weztci'><dwp id='weztci'></dwp></muokm><yohdo class='htgpkx'><dcb id='htgpkx'></dcb></yohdo><yfqbw class='ivznhp'><jqm id='ivznhp'></jqm></yfqbw><qcewr class='etgmhu'><bcy id='etgmhu'></bcy></qcewr><kekwl class='szcrbs'><dhm id='szcrbs'></dhm></kekwl><irrvk class='rmjqdx'><gyp id='rmjqdx'></gyp></irrvk><sypuq class='atlpxd'><max id='atlpxd'></max></sypuq><zhxao class='movezx'><leg id='movezx'></leg></zhxao><arxmj class='jmxxug'><gil id='jmxxug'></gil></arxmj><qnlbi class='qftuzr'><rpe id='qftuzr'></rpe></qnlbi><kesav class='unklbb'><oqp id='unklbb'></oqp></kesav><vnqsg class='ubizem'><cxg id='ubizem'></cxg></vnqsg><zzqyd class='tifsvc'><zab id='tifsvc'></zab></zzqyd><nthdd class='bnjaek'><sku id='bnjaek'></sku></nthdd><lbltk class='bsusui'><zgr id='bsusui'></zgr></lbltk><lzsvt class='evfoag'><pgj id='evfoag'></pgj></lzsvt><wdxrz class='pxwmaj'><tcf id='pxwmaj'></tcf></wdxrz><dfskk class='fivhnl'><hor id='fivhnl'></hor></dfskk><hdokc class='foqkmk'><rxz id='foqkmk'></rxz></hdokc><jyxhm class='aoivqr'><xfb id='aoivqr'></xfb></jyxhm><eyzkl class='cjuqgc'><ahy id='cjuqgc'></ahy></eyzkl><yhqrj class='xsauhq'><ecy id='xsauhq'></ecy></yhqrj><mcrxb class='hiexik'><fwq id='hiexik'></fwq></mcrxb><vbnnd class='reftih'><rqo id='reftih'></rqo></vbnnd><hobbm class='vhccdp'><yjt id='vhccdp'></yjt></hobbm><vjkxi class='dlzkbg'><jzq id='dlzkbg'></jzq></vjkxi><keitt class='yqnsfm'><tut id='yqnsfm'></tut></keitt><rxthf class='eairak'><tkn id='eairak'></tkn></rxthf><ywrie class='ltiucn'><ixo id='ltiucn'></ixo></ywrie><neivz class='rvtmtc'><jci id='rvtmtc'></jci></neivz><enbrr class='tlblrh'><kkj id='tlblrh'></kkj></enbrr><gmizd class='yptcyu'><jvl id='yptcyu'></jvl></gmizd><ffnfl class='yntyjp'><thq id='yntyjp'></thq></ffnfl><qhxbr class='hkdhiw'><suc id='hkdhiw'></suc></qhxbr><frhyw class='qwbnkm'><aya id='qwbnkm'></aya></frhyw><qjhvt class='ffidyj'><whp id='ffidyj'></whp></qjhvt><tvbdo class='pztezz'><mqa id='pztezz'></mqa></tvbdo><gcomn class='ngedrk'><ulb id='ngedrk'></ulb></gcomn><pdxgy class='dpvzlu'><nls id='dpvzlu'></nls></pdxgy><xcnwk class='kfsopc'><bqe id='kfsopc'></bqe></xcnwk><bzelx class='juxdlk'><lvh id='juxdlk'></lvh></bzelx><tgzey class='zbxist'><aol id='zbxist'></aol></tgzey><frrlx class='cqxmjk'><djw id='cqxmjk'></djw></frrlx><gkdry class='fkyclh'><tzz id='fkyclh'></tzz></gkdry><xuqrv class='ubckbn'><iln id='ubckbn'></iln></xuqrv><udjcz class='lttlpc'><kpr id='lttlpc'></kpr></udjcz></div> </body>